Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models

Clinical Cancer Research

Volumn 16, Issue 11, 2010, Pages 2989-2998

  Tentler, John J ^a   Bradshaw Pierce, Erica L ^a   Serkova, Natalie J ^a   Hasebroock, Kendra M ^a   Pitts, Todd M ^a   Diamond, Jennifer R ^a   Fletcher, Graham C ^b   Bray, Mark R ^b   Eckhardt, S Gail ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b EntreMed Inc Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [PHENYLVINYL 4 (4 METHYLPIPERAZIN 1 YL)] 6 (5 METHYL 2H PYRAZOL 3 YLAMINO)PYRIMIDINE; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; ENMD 2076; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PHOSPHOTRANSFERASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; KI-67 ANTIGEN; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953116873     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0325     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225-249
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487
3. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807
4. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-936
5. Fu J, Bian M, Jiang Q, et al. Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10.
6. Hu HM, Chuang CK, Lee M, et al. Genomic organization, expression, and chromosome localization of a third Aurora-related kinase gene, Aie1. DNA Cell Biol 2000;19:679-688
7. 2-M transition. J Cell Sci 2004;117:2523-2531
8. Kunitoku N, Sasayama T, Marumoto T, et al. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Dev Cell 2003;5: 242-248
9. Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-51795
10. Marumoto T, Zhang D, Saya H. Aurora A-A guardian of the poles. Nat Rev Cancer 2005;5:42-50.
11. Giet R, Glover DM. Drosophila Aurora B kinase is required for histone H3 phosphorylation and condensing recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 2001;152:669-682
12. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperdin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-294
13. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-280
14. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869-6875
15. Vader G, Lens S. The Aurora kinase family in cell division and cancer. Biochem Biophys Acta 2008;1786:60-72.
16. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-3065
17. Lam A, Ong K, Ho Y-H. Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Hum Pathol 2008;39: 599-604.
18. Gritsko TM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora A in human ovarian cancer. Clin Cancer Res 2003;9:1420-1426 (Pubitemid 36418396)
19. Li D, Zhu J, Firozi PF, et al. Overexpression of oncogenic STK15/ BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003;9:991-997 (Pubitemid 36323702)
20. Miyoshi Y, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001;92:370-373
21. Sen S, Zhou H, Zhang R-D, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-1329
22. Torchia EC, Chen Y, Sheng H, et al. A genetic variant of Aurora kinase A promotes genetic instability leading to highly malignant skin tumors. Cancer Res 2009;69:7207-7215
23. Tatsuka M, Katayama H, Ota T, et al. Multinuclearity and increased ploidy caused by overexpression of the Aurora B and Ip11-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811-4816 (Pubitemid 28503674)
24. Ota T, Suto S, Katamaya H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM1/AuroraB overexpression contributes to chromosome number instability. Cancer Res 2002;62: 5168-5177 (Pubitemid 35024587)
25. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-1648
26. Mountzios G, Terpos E, Dimopoulos M-A. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008;34:175-182
27. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24:3293-3298 (Pubitemid 46622069)
28. 18FFDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. Am J Roentgenol 2005;184: 579-587
29. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-4661
30. Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010;12:43-50.
31. Troiani T, Serkova NJ, Gustafson DL, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 2007;13:6450-6458
32. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232
33. Hirsch FR, Varell-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807
34. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262.
35. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-3168
36. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-3688
37. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104:4106-4111
38. Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol 2008;75:627-638
39. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218 (Pubitemid 29503984)
40. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5: 1280-1289
41. Ellis LM, Dallas NA, vanBuren G, Lim S, et al. Challenges in translating antiangiogenic therapy. Antiangiogenic Agents in Cancer Therapy. 2nd ed. Humana Press; 2007, pp. 323-330
42. Evelhoch JL, LoRusso PM, DelProsposto Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-3657
43. O'Connor JBP, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-195
44. Muruganandha M, Lupu M, Dyke JP, et al. Preclinical evaluation of tumor microvascular respond to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5T. Mol Cancer Ther 2006;5:1950-1957
45. Wu X, Jeong E-K, Emerson L, et al. Noninvasive evaluation of anti-angiogenic effect in a mouse tumor model by DCE-MRI with Gd-DPTA cystamine copolymers. Mol Pharmaceutics 2009;7:23-30.
46. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-2808
47. Antoch A, Kanja J, Bauer S, et al. Comparison of PET, CT and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45: 357-365
48. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevicizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
49. Tol J, Koopman M, Annemieke C, et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572
50. Bastos BR, Diamond J, Hansen D, et al. An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 adminstered orally to patients with advanced cancer. J Clin Oncol 2009; 27:15s.